Last reviewed · How we verify
Intensive multifactorial group
At a glance
| Generic name | Intensive multifactorial group |
|---|---|
| Also known as | Intensive group |
| Sponsor | Xiang Guang-da |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
- The MICRON Study - A Steno 1 Substudy
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (PHASE3)
- Nephropathy In Type 2 Diabetes and Cardio-renal Events (PHASE4)
- The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care. (NA)
- The Effect of Intensive Multifactorial Therapy on Endothelial Function in Newly Diagnosed Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensive multifactorial group CI brief — competitive landscape report
- Intensive multifactorial group updates RSS · CI watch RSS
- Xiang Guang-da portfolio CI